证券代码：002799 证券简称：环球印务 公告编号：2023-031 西安环球印务股份有限公司 第五届监事会第十九次会议决议公告 经全体与会监事认真审议，作出决议如下： 1、审议通过《西安环球印务股份有限公司 2023 年半年度报告及其摘要》 经审核，监事会认为董事会编制和审议的公司2023年半年度报告的程序符合法律、 行政法规及中国证监会的规定，报告内容真实、准确、完整地反映了上市公司的实际情 况，不存在任何虚假记载、误导性陈述或者重大遗漏。 内容详见公司 2023 年 8 月 10 日披露于巨潮资讯网（http://www.cninfo.com.cn）的 《西安环球印务股份有限公司 2023 年半年度报告》，披露于《中国证券报》、《证券时报》 及巨潮资讯网（http://www.cninfo.com.cn）的《西安环球印务股份有限公司 2023 年半年 度报告摘要》。 审议结果：经表决，同意 3 票，反对 0 票，弃权 0 票。 2、审议通过《关于控股股东及其他关联方占用公司资金、公司对外担保情况的议 案》 本公司及全体监事保证本公告内容真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏。 一、监 ...

独立董事关于第五届董事会第二十四次会议相关事项 的独立意见 根据《上市公司治理准则》等相关法律法规及《西安环球印务股份有限公司章程》 （以下简称"《公司章程》"）的有关规定，我们作为西安环球印务股份有限公司（以 下简称"公司"）的独立董事，对 2023 年 8 月 9 日召开的公司第五届董事会第二十四 次会议相关事项发表如下独立意见： 一、《关于控股股东及其他关联方占用公司资金、公司对外担保情况的议案》 根据《上市公司独立董事规则》、《上市公司治理准则》、《上市公司监管指引第 8 号——上市公司资金往来、对外担保的监管要求》、《深圳证券交易所股票上市规则》 等有关法律法规及《公司章程》的规定，作为公司的独立董事，我们本着实事求是的 原则以及对公司和全体股东负责的态度，基于独立判断的立场，对公司 2023 年半年 度对外担保情况和控股股东及其他关联方占用公司资金情况进行了认真细致的核查， 现发表独立意见如下： 截至 2023 年 6 月 30 日，公司不存在控股股东及其他关联方非经营性占用公司资 金的情况。公司能严格控制对外担保风险，截至 2023 年 6 月 30 日，公司除为控股子 公司提供担保外，不存在为 ...

西安环球印务股份有限公司 关于参加"2023年陕西辖区上市公司 投资者集体接待日暨2022年度业绩说明会"的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 西安环球印务股份有限公司（以下简称"公司"）已于 2023 年 4 月 29 日在 巨潮资讯网（www.cninfo.com.cn）上披露《2022 年年度报告》。为促进上市公司 规范运作、健康发展，增强上市公司信息透明度，加强与广大投资者沟通交流， 进一步提升投资者关系管理水平，陕西上市公司协会根据陕西证监局工作部署， 联合深圳市全景网络有限公司举办"2023 年陕西辖区上市公司投资者集体接待 日暨 2022 年度业绩说明会活动"。 届时，公司董事长雷永泉先生；董事、总经理孙学军先生；副总经理、董 事会秘书、总会计师林蔚女士将通过互动平台与投资者进行网络沟通和交流，欢 迎广大投资者踊跃参加！ 本次业绩说明会的活动时间为 2023 年 5 月 16 日（星期二）15:00-17:00。 投资者可登陆"全景路演"（http://rs.p5w.net）参与本次业绩说明会。 为充分尊重投资者、提升交流的针对 ...

Financial Performance - The company's operating revenue for 2022 was ¥2,966,656,380.11, representing a 1.03% increase compared to ¥2,936,304,792.98 in 2021[19] - The net profit attributable to shareholders for 2022 was ¥90,176,711.03, a decrease of 15.21% from ¥106,357,144.47 in 2021[19] - The net profit after deducting non-recurring gains and losses was ¥76,242,658.45, down 14.44% from ¥89,110,443.62 in the previous year[19] - The net cash flow from operating activities was negative at -¥27,273,965.48, a decline of 123.19% compared to ¥117,613,585.10 in 2021[19] - Basic earnings per share decreased by 14.29% to ¥0.36 from ¥0.42 in 2021[19] - Total assets at the end of 2022 reached ¥2,604,514,578.00, a significant increase of 59.04% from ¥1,637,617,535.07 in 2021[19] - The net assets attributable to shareholders rose by 109.14% to ¥1,586,106,872.49 from ¥758,397,541.67 in 2021[19] - The company achieved a total revenue of 2.967 billion yuan in 2022, representing a year-on-year growth of 1.05%, while the net profit attributable to shareholders decreased by 15.30% to 90 million yuan[58] - The internet digital marketing sector contributed ¥2,012,185,418.95, accounting for 67.83% of total revenue, with a growth of 4.20% from the previous year[68] - Revenue from the North China region surged by 78.82% to ¥1,638,774,048.16, significantly increasing its share of total revenue to 55.24%[68] - The gross profit margin for the internet digital marketing sector was 3.82%, reflecting a slight decrease of 0.52% compared to the previous year[70] - The gross profit margin for the printing and packaging supply chain business was 11.15%, with a year-on-year increase of 0.23%[70] - The company's total operating costs were ¥2,687,335,817.49, remaining stable compared to the previous year[74] - Revenue from overseas sales decreased by 34.43% to ¥12,202,298.82, indicating challenges in international markets[68] Investment and Capital Management - The company successfully issued 68.04 million new shares in December 2022, raising a total of 750 million yuan to enhance operational vitality and promote structural optimization[61] - The company is advancing the "Global Printing Expansion and Green Packaging Intelligent Manufacturing Industrial Park" project, which commenced in 2021, to support future smart, green, and digital factory implementations[60] - The company has committed to invest RMB 55 million in the expansion of its printing and green packaging smart manufacturing industrial park, with 19.47% of the investment completed as of the reporting period[102] - For the pharmaceutical packaging folding box expansion project, the company has committed RMB 25 million, with 28.37% of the investment completed[102] - The company raised a total of RMB 750,481,200.00 through a private placement of 68,040,000 shares at an issue price of RMB 11.03 per share, with a net amount of RMB 737,532,619.79 after deducting related issuance costs[101] - The company plans to use up to RMB 400 million of idle raised funds to temporarily supplement working capital, with a usage period not exceeding 12 months from the board's approval date[103] - The company has not engaged in any significant equity or non-equity investments during the reporting period[98][99] - The company has not utilized any idle raised funds for temporary working capital as of December 31, 2022[103] - As of December 31, 2022, the company had unused raised funds amounting to 100 million yuan, which will be allocated for subsequent investment projects[104] Research and Development - Research and development expenses amounted to ¥51,613,861.34, a decrease of 1.35% compared to the previous year[78] - The company has focused on technological innovation, particularly in drug packaging technology, enhancing product quality and production efficiency[80] - The company is increasing R&D investment to adapt to technological advancements in the packaging industry, focusing on automation and digitalization[137] - The company has obtained 25 new patents and 3 software copyrights during the reporting period, bringing the total to 205 intellectual property rights, including 130 patents and 75 software copyrights, maintaining its leading position in the industry[41] - The number of R&D personnel decreased by 12.09% from 215 in 2021 to 189 in 2022, with the proportion of R&D staff dropping from 19.37% to 17.76%[83] Market Strategy and Expansion - The company aims to expand its pharmaceutical packaging business, leveraging the projected 3%-6% annual growth rate of the global pharmaceutical market from 2022 to 2026[28] - The company is focusing on developing high-end packaging solutions for fast-moving consumer goods and health products, targeting mid to high-end markets[33] - The digital marketing segment is expected to grow as brands increasingly invest in digital marketing, with a focus on optimizing marketing effectiveness through data-driven strategies[31] - The company is actively pursuing the integration of the supply chain and innovating its business model to achieve transformation and upgrade based on traditional supply chain models[123] - The company plans to expand its internet digital marketing business by entering the live e-commerce sector and leveraging its digital marketing experience in the metaverse, focusing on virtual digital image creation and virtual idol IP operations[121] - The company is focusing on expanding its market presence through new product development and technological advancements in packaging solutions[82] - The company is committed to enhancing post-merger management to maximize synergies from acquisitions[144] Governance and Management - The company appointed Lei Yongquan as the new chairman on January 10, 2023, following the retirement of Li Yiling due to reaching the legal retirement age[166] - The current chairman, Lei Yongquan, has a background in finance and has held various senior positions in related companies since 2012[167] - The company has experienced a change in its board of directors, with Lei Yongquan being elected as chairman and Sun Xuejun continuing as general manager[166] - The management team consists of experienced professionals with backgrounds in finance, engineering, and management, contributing to the company's strategic direction[168] - The company is actively managing its governance structure to ensure effective oversight and strategic decision-making[166] - The company has a commitment to transparency, with detailed meeting resolutions published on the official information disclosure platform[183] - The board of directors held a total of 19 meetings during the reporting period, with resolutions disclosed on various dates[183] Employee and Compensation Policies - The total number of employees at the end of the reporting period was 1,064, with 571 in the parent company and 493 in major subsidiaries[193] - The company has implemented a performance-oriented compensation and performance management system to enhance employee motivation and skills[194] - The company emphasizes employee training as a key factor for talent development and performance improvement, with plans covering various dimensions such as safety, management, and technical skills[195] - The total pre-tax remuneration for directors, supervisors, and senior management during the reporting period amounted to CNY 5.456 million[180] - The independent directors received an annual salary of CNY 50,000 each (tax included) for the year 2022[180] Risk Management - The company recognizes the risks associated with national policy adjustments and plans to closely monitor policy directions to adapt its development goals and strategies accordingly[132] - The company faces risks from intensified industry consolidation and competition in the digital marketing sector, necessitating continuous improvement in its service capabilities[133] - The company is addressing the challenges of rapid scale expansion by optimizing internal processes and enhancing talent acquisition and training to mitigate management risks[136] - The company has a net accounts receivable of 451 million yuan, which poses a risk of bad debts if customer conditions deteriorate[143] - The company is facing risks from fluctuations in raw material prices, particularly industrial packaging paper, which could affect operating profits[140] Profit Distribution Policy - The profit distribution policy emphasizes continuity and stability, prioritizing cash dividends while considering sustainable development[196] - The company plans to distribute cash dividends of no less than 20% of the distributable profits for the next three years, provided there are no major investment plans or significant capital expenditures[198] - In a mature stage without major capital expenditures, the minimum cash dividend proportion should reach 80% of the profit distribution[198] - The company may conduct mid-term cash dividends based on profitability and funding needs, with specific plans approved by the board and shareholders[199]

Financial Performance - The company's operating revenue for Q1 2023 was ¥696,925,501.44, representing a 10.03% increase compared to ¥633,419,466.40 in the same period last year[4] - Net profit attributable to shareholders was ¥28,729,049.41, up 4.84% from ¥27,402,907.36 year-on-year[4] - Total operating revenue for Q1 2023 reached ¥696,925,501.44, an increase of 10% compared to ¥633,419,466.40 in Q1 2022[22] - The net profit for Q1 2023 was CNY 32,498,774.16, an increase of 1.79% compared to CNY 31,925,678.59 in Q1 2022[24] - The total comprehensive income attributable to the parent company was CNY 28,729,049.41, an increase from CNY 27,402,907.36 in the previous year[24] - The basic earnings per share remained stable at CNY 0.09, unchanged from Q1 2022[24] Cash Flow and Liquidity - The net cash flow from operating activities was negative at -¥10,698,900.14, a decline of 141.46% compared to ¥25,807,505.26 in the previous year[4] - The cash flow from operating activities showed a net outflow of CNY -10,698,900.14, a significant decrease from the previous year's inflow of CNY 25,807,505.26[25] - The company reported a decrease in cash flow from operating activities, indicating potential challenges in cash generation[25] - The cash balance at the end of the reporting period is RMB 711,217,748.73, down from RMB 906,522,100.48 at the beginning of the year[19] - The cash and cash equivalents at the end of the period were CNY 682,889,219.70, down from CNY 233,565,112.62 at the end of Q1 2022[27] - The company incurred a cash outflow of CNY 73,790,814.76 in investment activities, compared to CNY 7,785,033.24 in the same period last year[27] - The cash flow from financing activities resulted in a net outflow of CNY -119,900,261.61, compared to CNY -61,006,303.84 in Q1 2022[27] Assets and Liabilities - Total assets decreased by 4.46% to ¥2,488,444,593.26 from ¥2,604,514,578.00 at the end of the previous year[4] - Accounts receivable increased to ¥546,801,168.93 from ¥451,360,796.25, showing a growth of about 21%[21] - Total liabilities decreased to ¥771,114,976.93 from ¥919,683,735.82, a decline of approximately 16.1%[21] - The company's equity attributable to shareholders increased by 1.81% to ¥1,614,835,921.90 from ¥1,586,106,872.49 at the end of the previous year[4] - The company's equity attributable to shareholders increased to ¥1,614,835,921.90 from ¥1,586,106,872.49, reflecting a growth of about 1.8%[21] Operational Metrics - Total operating costs amounted to ¥659,545,187.78, up from ¥601,879,022.53, reflecting a rise of approximately 9.6%[22] - The company incurred a credit impairment loss of ¥5,841,905.12, compared to a loss of ¥1,855,884.71 in the previous year[22] - Inventory decreased by 47.77% to ¥49,875,558.27, attributed to increased sales and reduced stocking[9] - Inventory decreased significantly to ¥49,875,558.27 from ¥95,500,351.74, a reduction of approximately 47.8%[21] - Research and development expenses were reported at ¥14,132,285.59, down from ¥16,502,638.89, a decrease of approximately 15.4%[22] Shareholder Information - The total number of common shareholders at the end of the reporting period is 20,804[12] - The largest shareholder, Shaanxi Pharmaceutical Holdings Group Co., Ltd., holds 36.42% of shares, totaling 116,550,000 shares[12] Investments and Projects - Cash paid for fixed asset purchases surged by 742.03% to ¥65,552,148.76, reflecting significant investments in key production equipment[10] - The company repaid bank loans amounting to ¥253,899,351.46, an increase of 89.16% compared to the previous year[10] - The company is constructing a green packaging smart manufacturing industrial park, which includes primary and secondary pharmaceutical packaging production centers and a technology R&D center[16] - The registered capital for the new materials project company in Tianjin is set to be no less than RMB 80 million, with a total investment of at least RMB 100 million[17] Other Information - The company maintained a stable capital reserve of ¥714,687,690.36, unchanged from the previous period[21] - The company has not disclosed any new product developments or market expansion strategies in this report[28]

投资者关系活动记录表 证券代码： 002799 证券简称：环球印务 西安环球印务股份有限公司 投资者关系活动记录表 编号：2017-002 | --- | --- | --- | |-------------------------|---------------------------------|---------------------------------------------------------------------------------------------------------------------------| | | | | | | ■ | 特定对象调研 □分析师会议 | | 投资者关系活动类 | □ | 媒体采访 □业绩说明会 | | 别 | □ □ 现场参观 | 新闻发布会 □路演活动 | | 参与单位名称 及人员姓名 | | □其他（请文字说明其他活动内容） 东北证券股份有限公司：唐凯 | | | | 北京市星石投资管理有限公司：王龙 | | 时间 | 2017 年 3 月 9 | 日 下午 14:00-16:00 | | 地点 公司接待人员 | 公司三楼证券投资部 ...

投资者关系活动记录表 1 证券代码： 002799 证券简称：环球印务 西安环球印务股份有限公司 投资者关系活动记录表 编号：2017-001 | --- | --- | --- | |-----------------------------|-------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | ■ | 特定对象调研 □分析师会议 | | 投资者关系活动类 | □ | 媒体采访 □业绩说明会 | | 别 | □ □ 现场参观 | 新闻 ...

投资者关系活动记录表 1 证券代码： 002799 证券简称：环球印务 西安环球印务股份有限公司 投资者关系活动记录表 编号：2017-004 | --- | --- | --- | |-----------------------------|----------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

投资者关系活动记录表 1 证券代码： 002799 证券简称：环球印务 西安环球印务股份有限公司 投资者关系活动记录表 编号：2017-003 | --- | --- | --- | |-------------------------|------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | ■ | 特定对象调研 □分析师会议 | | 投资者关系活动类 | □ | 媒体采访 □业绩说明会 | | 别 | □ □ 现场参观 | 新闻发布会 □路演活动 | | | | □其他（请文字说明其他活动内容） | | 参与单位名称 及人员姓名 | | 国信证券股份有限公司：丰毅 | | 时间 | 2017 年 11 月 | 10 日 下午 14 ...

Financial Performance - The company reported a revenue of CNY 1,337,846,668.70 for the first half of 2022, a decrease of 17.68% compared to CNY 1,625,130,768.07 in the same period last year[20]. - Net profit attributable to shareholders was CNY 60,213,794.07, down 22.62% from CNY 77,818,940.60 year-on-year[20]. - Basic and diluted earnings per share decreased to CNY 0.24, down 22.58% from CNY 0.31 in the same period last year[20]. - The company's operating revenue for the reporting period was ¥1,337,846,668.70, a decrease of 17.68% compared to ¥1,625,130,768.07 in the same period last year[67]. - The company's operating costs decreased by 18.68% to ¥1,180,903,132.68 from ¥1,452,150,021.94 year-on-year[67]. - The net profit for the first half of 2022 was CNY 68,920,718.90, a decrease from CNY 92,101,232.11 in the first half of 2021, which is a decline of around 25.14%[185]. - The total profit for the first half of 2022 was CNY 73,924,199.72, down from CNY 104,923,398.90 in the first half of 2021, reflecting a decline of about 29.54%[184]. Cash Flow and Liquidity - The net cash flow from operating activities increased significantly to CNY 35,540,255.46, a rise of 3,578.23% compared to CNY 966,233.16 in the previous year[20]. - The company reported a net increase in cash and cash equivalents of ¥7,450,861.59, compared to a decrease of ¥31,616,747.42 in the previous year[67]. - Cash and cash equivalents at the end of the reporting period were ¥305,141,629.07, a slight decrease of 0.85% from ¥299,361,975.03[72]. - The total cash inflow from financing activities was CNY 361,549,956.32, compared to CNY 264,323,567.81 in the previous year, reflecting a 37% increase in financing efforts[190]. - The total cash and cash equivalents at the end of the period increased to CNY 283,581,140.29 from CNY 260,444,662.53, marking a positive change in liquidity[190]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,750,462,739.97, reflecting a growth of 6.89% from CNY 1,637,617,535.07 at the end of the previous year[20]. - Current liabilities rose to CNY 802,670,111.71, up from CNY 741,040,523.41, indicating an increase of 8.5%[179]. - Non-current liabilities decreased to CNY 34,343,267.77 from CNY 52,048,370.07, a reduction of 34.0%[179]. - The total balance of restricted assets at the end of the reporting period was ¥22,145,241.14, down from ¥26,532,891.77 at the end of the previous year[4]. Research and Development - Research and development investment increased by 10.12% to ¥28,385,361.25 from ¥25,777,866.63 year-on-year[67]. - The company is increasing its research and development investments to keep pace with technological advancements in automation and artificial intelligence[96]. - The company has obtained 18 new patents and 3 software copyrights during the reporting period, with a total of 161 intellectual property rights, maintaining its leading position in the industry[47]. Market Position and Strategy - The company ranks 15th in the "2022 Top 100 Printing and Packaging Enterprises in China" list, indicating its leading position in the pharmaceutical packaging sector[36]. - The company is focusing on expanding its pharmaceutical packaging business, particularly in the chemical drug market, ensuring the achievement of operational goals[31]. - The company aims to maintain stable growth in the pharmaceutical packaging sector while exploring new business models in digital marketing and supply chain management[36]. - The company is actively developing high-end packaging for fast-moving consumer goods, health products, and cosmetics, targeting well-known domestic and international clients[37]. Environmental and Social Responsibility - The company emphasizes safety and environmental protection, implementing strict safety management and training programs[34]. - The company has established two sets of organic waste gas treatment facilities, which are operating well without any abnormalities during the reporting period[111]. - The company is committed to social responsibility, providing educational subsidies to two employees to enhance their skills[117]. - The company has implemented measures to reduce carbon emissions, although specific results were not detailed in the report[116]. Corporate Governance - The company has maintained stable governance with no changes in its board or management during the reporting period[106]. - The controlling shareholder, Shaanxi Medical Holdings Group, holds a 65% stake in the company and has made commitments to avoid related party transactions[121]. - The company has committed to ensuring that any necessary transactions with related parties will adhere to market principles and fair pricing[121]. Future Outlook - Future outlook includes potential market expansion and new product development strategies to enhance revenue streams[183]. - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[195].